source
- Novartis reports nine tumor cases in patients treated with Zolgensma gene therapyNovartis has confirmed that nine cases of tumors have been reported in patients who received its spinal muscular atrophy gene therapy, Zolgensma. The company says two cases are confirmed and seven…
- British biotech T-Therapeutics raises $133 million Series B to advance bispecific T-cell engagersT-Therapeutics, a British biotech, announced a $133 million Series B financing to advance its next-generation T-cell engager therapeutics. The round was co-led by Advent Life Sciences and the Brit…